These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 26198343)

  • 1. Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access.
    Hankins C; Macklin R; Warren M
    J Int AIDS Soc; 2015; 18(4 Suppl 3):19973. PubMed ID: 26198343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
    Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
    J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact, cost and cost-effectiveness of oral pre-exposure prophylaxis in sub-Saharan Africa: a scoping review of modelling contributions and way forward.
    Case KK; Gomez GB; Hallett TB
    J Int AIDS Soc; 2019 Sep; 22(9):e25390. PubMed ID: 31538407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America.
    Ravasi G; Grinsztejn B; Baruch R; Guanira JV; Luque R; Cáceres CF; Ghidinelli M
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21113. PubMed ID: 27760687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy.
    Cáceres CF; Borquez A; Klausner JD; Baggaley R; Beyrer C
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21108. PubMed ID: 27760685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.
    Nichols BE; Boucher CAB; van der Valk M; Rijnders BJA; van de Vijver DAMC
    Lancet Infect Dis; 2016 Dec; 16(12):1423-1429. PubMed ID: 27665989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
    Cambiano V; Miners A; Dunn D; McCormack S; Ong KJ; Gill ON; Nardone A; Desai M; Field N; Hart G; Delpech V; Cairns G; Rodger A; Phillips AN
    Lancet Infect Dis; 2018 Jan; 18(1):85-94. PubMed ID: 29054789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
    PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preexposure prophylaxis revolution; from clinical trials to programmatic implementation.
    Mugo NR; Ngure K; Kiragu M; Irungu E; Kilonzo N
    Curr Opin HIV AIDS; 2016 Jan; 11(1):80-6. PubMed ID: 26575147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil.
    Luz PM; Osher B; Grinsztejn B; Maclean RL; Losina E; Stern ME; Struchiner CJ; Parker RA; Freedberg KA; Mesquita F; Walensky RP; Veloso VG; Paltiel AD
    J Int AIDS Soc; 2018 Mar; 21(3):e25096. PubMed ID: 29603888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand.
    Suraratdecha C; Stuart RM; Manopaiboon C; Green D; Lertpiriyasuwat C; Wilson DP; Pavaputanon P; Visavakum P; Monkongdee P; Khawcharoenporn T; Tharee P; Kittinunvorakoon C; Martin M
    J Int AIDS Soc; 2018 Jul; 21 Suppl 5(Suppl Suppl 5):e25129. PubMed ID: 30033559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PrEP implementation: moving from trials to policy and practice.
    Cáceres CF; O'Reilly KR; Mayer KH; Baggaley R
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20222. PubMed ID: 26198349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL; Shelley K; Nicol MR
    Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies.
    Gomez GB; Borquez A; Case KK; Wheelock A; Vassall A; Hankins C
    PLoS Med; 2013; 10(3):e1001401. PubMed ID: 23554579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China.
    Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K
    AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa.
    Hosek S; Celum C; Wilson CM; Kapogiannis B; Delany-Moretlwe S; Bekker LG
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21107. PubMed ID: 27760684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 - 2023).
    Moyo E; Barham L; Mhango M; Musuka G; Dzinamarira T
    J Infect Public Health; 2022 Oct; 15(10):1147-1155. PubMed ID: 36162151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058.
    van de Vijver DAMC; Richter AK; Boucher CAB; Gunsenheimer-Bartmeyer B; Kollan C; Nichols BE; Spinner CD; Wasem J; Schewe K; Neumann A
    Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
    Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
    J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.